Tweetovi

Blokirali ste korisnika/cu @MerayoDr

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MerayoDr

  1. Prikvačeni tweet

    Inmunología clinca y básica, excelente oportunidad, excelentes ponentes talla internacional. Mty, Mexico 👇🏻🧪

    Poništi
  2. Muy interesante y de aplicación del día a día 💡💡💡

    Poništi
  3. Thanks to Martín and Lalo for this wonderful year! And happy to see next month their beginning as fellows in internal medicine at our home! – mjesto: Departamento de Reumatología e Inmunología

    Poništi
  4. 30. sij
    Poništi
  5. Pragmatic Language Dysfunction in SLE - The Rheumatologist 👇🏻👇🏻🔦🔦👇🏻👇🏻

    Poništi
  6. Upadacitinib and sarilumab now on fight 🤜🏼🤜🏼🤜🏼 vs RA 🤛🏻🤛🏻🤛🏻🤛🏻

    Poništi
  7. 24. sij

    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases

    Poništi
  8. 22. sij

    New GLADEL publication that compares the 2019 EULAR/ACR, 2012 SLICC and 1997 ACR classification criteria for . It's at

    Poništi
  9. Poništi
  10. 21. sij

    After 2 years of working with our arthralgia cohort, in our rapid diagnostic program for (rheuma-check), focusing on and , we present this publication from January 2020. An effort by all the team.

    Prikaži ovu nit
    Poništi
  11. Poništi
  12. 20. sij

    NEW ONLINE: Tofacitinib is associated with increased risk of admission to hospital for serious in patients with , including a 2-fold higher risk of compared to all bDMARDs

    Prikaži ovu nit
    Poništi
  13. Poništi
  14. Key points: ✅first cause failure Arth👉🏻infec ✅dx needs t/b ASAP⏱ ✅RD px almost 1/3 negative culture🦠 ✅why delay in RD?👉🏻flare mimics infec (clinical, Lab, etc) so ⬆️⬆️⬆️suspicious index Limits: small N, retrospec. Take a look here 👇🏻🤓👇🏻

    Poništi
  15. Very interesting topic; in fact px with cancer on immunotherapy who positivize RF and/or ANA seems to have better response vs negative px😮👆🏻😮 🤝

    Poništi
  16. Lower risk with vs others antiTNF. One more time 🤷🏼‍♂️👇🏻✅👆🏻

    Poništi
  17. RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors - The Rheumatologist // we need more info about goli and certoli, but nice numbers for etanercept 👇🏻‼️👇🏻

    Poništi
  18. Poništi
  19. Poništi
  20. Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·